Immuron Ltd (IMRN)
2.45
+0.04
(+1.66%)
USD |
NASDAQ |
Apr 18, 16:00
2.45
0.00 (0.00%)
After-Hours: 20:00
Immuron Cash from Financing (TTM): -0.0306M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.0306M |
June 30, 2023 | -0.0296M |
December 31, 2022 | -0.0295M |
June 30, 2022 | -0.0306M |
December 31, 2021 | -0.1079M |
June 30, 2021 | 19.36M |
December 31, 2020 | 19.38M |
Date | Value |
---|---|
June 30, 2020 | 0.7935M |
December 31, 2019 | 2.311M |
June 30, 2019 | 1.448M |
December 31, 2018 | 3.477M |
June 30, 2018 | 3.288M |
December 31, 2017 | 3.994M |
June 30, 2017 | 6.456M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.1079M
Minimum
Dec 2021
19.38M
Maximum
Dec 2020
4.306M
Average
0.382M
Median
Cash from Financing (TTM) Benchmarks
Mesoblast Ltd | 74.50M |
CERo Therapeutics Holdings Inc | -- |
Alterity Therapeutics Ltd | 33.78M |
Kazia Therapeutics Ltd | 8.600M |
Immutep Ltd | 13.70M |